Compare · FLDM vs TXG
FLDM vs TXG
Side-by-side comparison of Fluidigm Corporation (FLDM) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- FLDM operates in Capital Goods, while TXG operates in Industrials - the two are in different parts of the market.
- TXG is the larger of the two at $9.76B, about 39.9x FLDM ($244.6M).
- TXG has hit the wire 5 times in the past 4 weeks while FLDM has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 0 for FLDM).
- Company
- Fluidigm Corporation
- 10x Genomics Inc.
- Price
- $3.70-7.27%
- $22.10+3.10%
- Market cap
- $244.6M
- $9.76B
- 1M return
- -
- +5.59%
- 1Y return
- -
- +160.46%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest FLDM
- No More Free COVID-19 At-Home Tests, Federal Government Says
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units
- SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units
- SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Witney Frank was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Paya Carlos V was granted 30,914 shares, increasing direct ownership by 44% to 100,468 units
- SEC Form 4: Casdin Eli was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Clague Laura was granted 30,914 shares, increasing direct ownership by 65% to 78,415 units
Latest TXG
- SEC Form DEFA14A filed by 10x Genomics Inc.
- SEC Form DEF 14A filed by 10x Genomics Inc.
- 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
- SEC Form 4 filed by Saxonov Serge
- 10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
- 10x Genomics upgraded by William Blair
- SEC Form 4 filed by Saxonov Serge
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.